Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Moexipril Hydrochloride

FDA-approved product (tablet, oral), marketed as Moexipril Hydrochloride, Univasc.

Registered studies
12
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Moexipril Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ace inhibitors, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

12registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Moexipril Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Moexipril Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

    NCT07547878 · start 2026-04-30

    Registered record
    Registry ID
    NCT07547878
    Conditions
    Chronic Kidney Disease; Type 2 Diabetes
    Interventions
    Finerenone; Semaglutide; Lotensin; Capoten; Enalapril; Monopril; Lisinopril; Univasc; Aceon; Accupril; Altace; Mavik; Edarbi; Atacand; Avapro; Cozaar; Benicar; Micardis; Diovan; Invokana; Farxiga; Jardiance; Ertugliflozin; Brenzavvy; Sotagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04-30
    Completion
    2029-03-31
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 2 Diabetes
    InterventionFinerenone; Semaglutide; Lotensin; Capoten +21 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study

    NCT07262710 · start 2025-12-01

    Registered record
    Registry ID
    NCT07262710
    Conditions
    Post-stroke Pneumonia
    Interventions
    angiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2026-08-19
    Enrolment
    13,656

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-stroke Pneumonia
    Interventionangiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

    NCT05498675 · start 2021-09-01

    Registered record
    Registry ID
    NCT05498675
    Conditions
    Sacubitril/Valsartan; Hypertension; Obesity
    Interventions
    Sacubitril / Valsartan Oral Tablet [Entresto]; ACEI/ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-09-01
    Completion
    2027-06-30
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSacubitril/Valsartan; Hypertension; Obesity
    InterventionSacubitril / Valsartan Oral Tablet [Entresto]; ACEI/ARB
    PhaseNot recorded
    Registry statusRecruiting

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted

  • Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery

    NCT01669434 · start 2015-06-01

    Registered record
    Registry ID
    NCT01669434
    Conditions
    Hypotension on Induction
    Interventions
    ACEI continuation; ACEI omission
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-06-01
    Completion
    2016-12-01
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypotension on Induction
    InterventionACEI continuation; ACEI omission
    PhasePhase 4
    Registry statusCompleted

  • ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

    NCT01867047 · start 2013-06

    Registered record
    Registry ID
    NCT01867047
    Conditions
    Adverse Effects of Angiotensin-converting-enzyme Inhibitors; Hypotension
    Interventions
    ACE-I Cessation group; ACE-I Continuation group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2013-06
    Completion
    2016-06-24
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Effects of Angiotensin-converting-enzyme Inhibitors; Hypotension
    InterventionACE-I Cessation group; ACE-I Continuation group
    PhaseNot applicable
    Registry statusTerminated

  • Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions

    NCT00834067 · start 2003-10

    Registered record
    Registry ID
    NCT00834067
    Conditions
    Healthy
    Interventions
    Moexipril HCl/hydrochlorothiazide 15/25 mg tablets; UNIRETIC® 15/25 mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-10
    Completion
    2003-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMoexipril HCl/hydrochlorothiazide 15/25 mg tablets; UNIRETIC® 15/25 mg tablets
    PhasePhase 1
    Registry statusCompleted

  • Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions

    NCT00835042 · start 2003-10

    Registered record
    Registry ID
    NCT00835042
    Conditions
    Healthy
    Interventions
    Moexipril HCl/hydrochlorothiazide 15/25 mg tablets; UNIRETIC® 15/25 mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-10
    Completion
    2003-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMoexipril HCl/hydrochlorothiazide 15/25 mg tablets; UNIRETIC® 15/25 mg tablets
    PhasePhase 1
    Registry statusCompleted

  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted

  • Moexipril for Primary Biliary Cirrhosis

    NCT00588302 · start 2003-06

    Registered record
    Registry ID
    NCT00588302
    Conditions
    Primary Biliary Cirrhosis
    Interventions
    Moexipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-06
    Completion
    2007-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Biliary Cirrhosis
    InterventionMoexipril
    PhasePhase 2
    Registry statusCompleted

  • A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions

    NCT00990301

    Registered record
    Registry ID
    NCT00990301
    Conditions
    Healthy
    Interventions
    Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.; Uniretic® 15mg/25mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMoexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.; Uniretic® 15mg/25mg Tablets
    PhasePhase 1
    Registry statusCompleted

  • A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions

    NCT00992862

    Registered record
    Registry ID
    NCT00992862
    Conditions
    Healthy
    Interventions
    Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.; Univasc® 15mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMoexipril HCl 15mg Tablets, Paddock Laboratories, Inc.; Univasc® 15mg Tablets
    PhasePhase 1
    Registry statusCompleted